I now have rich, comprehensive content from multiple authoritative textbooks. Here is the full, synthesized answer:
Immune Reconstitution Inflammatory Syndrome (IRIS)
Definition
IRIS is a paradoxical worsening of clinical status that occurs when a previously severely immunosuppressed patient's immune system begins to recover. It manifests as an exuberant, often disorganized host inflammatory response to previously recognized or subclinical antigens. The syndrome most commonly develops after initiation of antiretroviral therapy (ART) in HIV-infected patients. - Murray & Nadel's Textbook of Respiratory Medicine, p. 2866
Types
| Type | Description |
|---|
| Paradoxical IRIS | Patient has a known infection, responds to treatment, then paradoxically worsens after starting ART |
| Unmasking IRIS | Patient starts ART without a known infection; immune recovery reveals a previously subclinical (silent) infection |
- Fishman's Pulmonary Diseases and Disorders, p. 2371-2372
Pathogenesis
IRIS is thought to result from:
- Dysregulation of rising CD4+ T cells that are highly antigen-specific, mounting a disproportionate inflammatory response
- Hyperresponsiveness of the innate immune system to helper T cells
- In cryptococcal IRIS specifically: pre-ART elevations in Th2 and Th17 cytokines (IL-17, IL-4), reduced pro-inflammatory cytokines (TNF-alpha, G-CSF), and high titers of serum/CSF cryptococcal antigen
There is an inverse correlation between baseline CD4 count and the probability of developing IRIS - lower CD4 counts at ART initiation mean higher IRIS risk. - Firestein & Kelley's Textbook of Rheumatology
Risk Factors
- CD4 count <50-100 cells/μL at ART initiation (greatest risk below 50 cells/μL)
- Initiating ART shortly after diagnosing an opportunistic infection
- Rapid virologic and immunologic response to ART
- High pathogen burden at time of ART initiation
- IRIS can also occur in transplant recipients when immunosuppressive therapy is withdrawn rapidly
Timing
The majority of cases occur within the first 1-3 months after ART initiation, though cases can present several months later. - Murray & Nadel's, p. 2866
Common Triggers / Associated Conditions
Infections (most common):
- Mycobacteria - M. tuberculosis and MAC are the most frequently encountered
- Fungal - Cryptococcus (especially meningitis), PCP (Pneumocystis)
- Viral - CMV
- Leprosy (can flare after ART initiation)
Non-infectious:
-
Sarcoidosis (may be unmasked or worsen)
-
Autoimmune diseases appearing de novo: RA, SLE, polymyositis, autoimmune hepatitis, Guillain-Barre syndrome, adult-onset Still's disease
-
Malignancies - tumors may paradoxically worsen
-
Cerebral CD8 lymphocytosis, alopecia universalis, terminal ileitis
-
Firestein & Kelley's Textbook of Rheumatology; Murray & Nadel's Respiratory Medicine
Diagnostic Criteria
All of the following should be present:
- Diagnosis of AIDS
- Currently on ART with evidence of increase in CD4 count and decrease in HIV viral load
- Exaggerated inflammatory response to infection
- Inflammatory symptoms appearing during ART that cannot be explained by another cause (other opportunistic infections, drug toxicity, treatment failure)
- Firestein & Kelley's Textbook of Rheumatology, p. 6620-6622
Special Considerations: Cryptococcal Meningitis-IRIS
This warrants particular caution because the CNS has limited anatomical flexibility, making IRIS here more lethal than extra-CNS IRIS.
- Deferring ART by 4-5 weeks (rather than starting immediately) after diagnosing cryptococcal meningitis is associated with significantly improved survival, especially in patients with few CSF white cells
- This is the one important exception to the general rule of starting ART as soon as possible after diagnosing an OI
- Screening for cryptococcal antigen (CrAg) in asymptomatic patients with CD4 <100 cells/mm³ before starting ART is WHO-recommended to prevent unmasking IRIS
- Goldman-Cecil Medicine; Fishman's Pulmonary Diseases, p. 2373-2375
TB-IRIS and the PredART Trial
- Prophylactic prednisone reduces the risk of TB-associated IRIS in high-risk individuals (CD4 <100 cells/μL, within 30 days of TB treatment initiation)
- Regimen: prednisone 40 mg/day x 14 days, then 20 mg/day x 14 days
- This was established in the PredART Clinical Trial, without increased risk of other severe infections or cancers
- TB-IRIS may contribute to long-term spirometric abnormalities in HIV/TB patients
- Murray & Nadel's Respiratory Medicine, p. 2866
Management
| Severity | Management |
|---|
| Mild IRIS | Continue ART; supportive care only |
| Moderate IRIS | NSAIDs to reduce inflammation |
| Severe IRIS (CNS, airway compromise) | Corticosteroids (prednisone 1.5 mg/kg/day x 2 weeks, then 0.75 mg/kg/day x 2 weeks) |
| Cryptococcal meningitis IRIS with raised ICP/cerebral edema | Corticosteroids under expert guidance (though steroids are otherwise unhelpful or detrimental in cryptococcal disease) |
-
ART should generally be continued in patients who develop IRIS; stopping is rarely necessary
-
Carefully consider each case individually; expert consultation recommended
-
JAK inhibitors - a recent clinical trial suggests they may be effective in preventing inflammatory complications of ART (emerging evidence)
-
Murray & Nadel's Respiratory Medicine, p. 2866; Goldman-Cecil Medicine; Firestein & Kelley's Rheumatology, p. 6630
Key Points Summary
| Feature | Detail |
|---|
| Setting | HIV/AIDS patients starting ART; also post-transplant on reduced immunosuppression |
| Timing | Typically 1-3 months after ART initiation |
| Hallmark | Paradoxical worsening despite improving CD4/viral load |
| Biggest risk factor | CD4 <50 cells/μL at ART initiation |
| Most common triggers | M. tuberculosis, MAC, Cryptococcus, PCP |
| Most dangerous manifestation | Cryptococcal meningitis-IRIS (CNS, high mortality) |
| Prevention (TB-IRIS) | Prophylactic prednisone (PredART protocol) |
| Prevention (Crypto-IRIS) | Delay ART 4-5 weeks; CrAg screening |
| Treatment backbone | Continue ART + steroids for severe cases |